In April 2016, the FDA approved the first biosimilar monoclonal antibody Remsima, developed from Remicade (infliximab, Janssen). Biosimilars provide significant cost savings for patients, but the potential differences between innovative drug and inexpensive duplicate raise questions regarding product usability. Read about the authors’ comparison of Remicade and Remsima using native mass spectrometry, ion mobility and quantitative peptide mapping, including the use of the AccuMAP™ Low pH Protein Digestion Kit.
A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. Pisupati, et al. (2017) ACS
Anal. Chem. 89, 4838.